Intravenous Iron Drugs Market - Industry Size, Share, Growth & Forecast 2028 | UnivDatos

 

Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body. The rising prevalence of chronic diseases such as kidney diseases and cancer glaucoma increase the demand for the supplement iron. and myopia has a significant contribution to the market for Intravenous Iron. For instance, as per the WHO, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Furthermore, the increasing malnutrition cases in underdeveloped and developing nations also catalyze the demand for the supplement industry including iron injections. Therefore, increasing demand for iron supplement is expected to drive the global Intravenous Iron Drugs market at a CAGR of 8%, during the forecast period.

COVID-19 has slowed the growth of the Intravenous Iron market, as countries were forced to implement lockdowns during the first half of 2020. Due to stringent government regulation and escalated COVID-19 cases, the hospitals engaged their resources in the COVID-19 treatment and postpended the inessential appointments during the pandemic

Unlock The Table of Content, And Request a Sample Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=28059

 According to UnivDatos Market Insights (UMI)’ research report “global intravenous iron drugs market”, the market is expected to witness robust growth during the forecast period 2021-2027F. This is mainly due to the increasing demand for supplement iron and rising anemia incidences.

Based on the product, the market has been categorized into iron dextran, iron sucrose, ferric carboxymaltose, and others. Amongst these, the ferric carboxymaltose segment is expected to witness significant growth during the forecast period. This is mainly due to its higher applications and reduced cost. Furthermore, the rising number of surgeries increases the number of postoperative anemia cases. For example, according to ISAPS, in 2020, 10,129,528 surgical procedures were performed.

Unlock The Table of Content, And Request a Sample Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=28059

Based on the application, the market has been categorized into chronic kidney disease, inflammatory bowel disease, cancer, and others. Among them, the chronic kidney disease segment is expected to have significant growth in the market owing to its higher number and the death caused by them. Furthermore, the due to heavy blood loss during dialysis is one of the major causes of anemia and drives the demand for the supplement iron. For instance, as per CDC, Kidney diseases are a leading cause of death in the United States. about 37 million US adults are estimated to have CKD, and most are undiagnosed.

Based on end-users, the market is classified into the market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals are expected to witness lucrative growth during the forecast period. This is mainly due to the presence of well-qualified professionals and their specialization in the treatment of multiple diseases. Furthermore, the rising prevalence of chronic diseases such as heart disease is responsible for the segmental growth in the intravenous iron drug market.

For a better understanding of the market adoption of the intravenous iron drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World North America holds a lucrative market share owing to favorable government policies and the presence of a large geriatric population in the region is attributed to the growth of the market in the region. For instance, according to the United Nations, the 60+ aged population was 962 million in 2017 which is more than twice what it was in 1980 at 382 million. The number of elderlies is expected to double again by 2050 and reach nearly 2.1 billion worldwide.

For More Informative Information, Please Visit Us – https://univdatos.com/report/intravenous-iron-drugs-market/

According to UnivDatos Market Insights (UMI)’, the key players with a considerable market share in the global intravenous iron drugs market are Vifor Pharma Management Ltd., AMAG Pharmaceuticals, Daiichi Sankyo Company, Ltd., Sanofi S.A., Pharmacosmos A/S, Shield Therapeutics Plc, AbbVie, Rockwell Medical, Americal Reagent, and Keryx Biopharmaceuticals Inc.

“Global Intravenous Iron Drugs Market” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and opportunities available for the market players. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on different parameters. This will help companies in the formulation of go-to-market strategies and identifying the blue ocean for its offerings.      

Market Segmentation:

1.      By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others)

2.      By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Others)

3.      By End-Users (Hospitals, Ambulatory Surgical Centers, and Others)

4.      By Region (North America, Europe, Asia-Pacific, Rest of the World)

5.      By Company (Vifor Pharma Management Ltd., AMAG Pharmaceuticals, Daiichi Sankyo Company, Ltd.,  Sanofi S.A., Pharmacosmos A/S, Shield Therapeutics Plc, AbbVie, Rockwell Medical, Americal Reagent, and Keryx Biopharmaceuticals Inc)

Key questions answered in the study:

1.      What are the current and future trends of the global intravenous iron drugs industry?

2.      How the industry has been evolving in terms of product, application, and end-users?

3.      How the competition has been shaping across the countries followed by their comparative factorial indexing?

4.      What are the key growth drivers and challenges for the global intravenous iron drugs industry?

5.      What is the customer orientation, purchase behavior, and expectations from the global Intravenous Iron Drugs suppliers across various region and countries?